BAY 559837
Latest Information Update: 23 Mar 2010
Price :
$50 *
At a glance
- Originator Bayer
- Class Antihyperglycaemics
- Mechanism of Action Vasoactive intestinal peptide type II receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 29 May 2002 Preclinical trials in Type-2 diabetes mellitus in USA (unspecified route)